Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
4.190
-0.220 (-4.99%)
Feb 21, 2025, 4:00 PM EST - Market closed
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Corvus Pharmaceuticals stock have an average target of 12.38, with a low estimate of 3.50 and a high estimate of 21. The average target predicts an increase of 195.47% from the current stock price of 4.19.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 14, 2025.
Analyst Ratings
The average analyst rating for Corvus Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +162.53% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +162.53% | Jan 2, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $8 → $14 | Buy | Reiterates | $8 → $14 | +234.13% | Nov 13, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $12 → $21 | Strong Buy | Maintains | $12 → $21 | +401.19% | Sep 16, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +90.93% | May 7, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.94
from -0.56
EPS Next Year
-0.50
from -0.94
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 10.5M | |||
| Avg | n/a | n/a | 2.6M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.95 | -0.46 | -0.43 | |||
| Avg | -0.94 | -0.50 | -0.63 | |||
| Low | -0.93 | -0.55 | -0.78 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.